Northern Trust Corp Has $2.23 Million Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Northern Trust Corp reduced its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 27.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 387,376 shares of the biotechnology company’s stock after selling 149,329 shares during the period. Northern Trust Corp owned about 1.82% of Enanta Pharmaceuticals worth $2,227,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new position in Enanta Pharmaceuticals in the 4th quarter worth about $26,000. Tower Research Capital LLC TRC increased its holdings in shares of Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 2,274 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $58,000. Wells Fargo & Company MN increased its holdings in shares of Enanta Pharmaceuticals by 69.6% during the 4th quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 6,518 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $105,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. JMP Securities reissued a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Stock Up 1.0%

Shares of NASDAQ:ENTA opened at $5.81 on Monday. The business has a 50 day moving average price of $5.42 and a 200 day moving average price of $6.40. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.09 and a twelve month high of $17.24. The company has a market cap of $124.20 million, a price-to-earnings ratio of -1.17 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. The business had revenue of $14.93 million for the quarter, compared to the consensus estimate of $15.96 million. Analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.